ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,025.99
      -0.95%
      US Tech 100
      20,874.00
      -1.46%
      Dow Jones
      44,303.40
      -0.99%
      Brent Oil
      74.945
      0.44%
      Bitcoin
      96,754.23
      0.27%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. USOTC

      6. UCB (PK) (UCBJY) Quote

      UCB (PK)

      UCB (PK) (UCBJY)

      USOTC
      97.76
      1.13
      (1.17%)
      Closed February 09 4:00PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      97.76
      Bid
      96.36
      Ask
      99.27
      Volume
      44,671
      97.20 Day's Range 98.11
      47.56 52 Week Range 100.66
      Market Cap
      37.07B
      Previous Close
      96.631
      Open
      97.874
      Last Trade
      6
      @
      97.75
      Last Trade Time
      Financial Volume
      $ 4,358,792
      VWAP
      97.5754
      Average Volume (3m)
      15,807
      Shares Outstanding
      379,189,796
      Dividend Yield
      0.94%
      PE Ratio
      209.21
      Earnings Per Share (EPS)
      0.9
      Revenue
      4.87B
      Net Profit
      343M

      About UCB (PK)

      UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

      Sector
      Pharmaceutical Preparations
      Industry
      Chemicals & Allied Products
      Website
      www.ucb.com
      Headquarters
      Brussels, Brussels-capital Region, Bel
      Founded
      1928
      UCB (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker UCBJY. The last closing price for UCB (PK) was $96.63. Over the last year, UCB (PK) shares have traded in a share price range of $ 47.56 to $ 100.66.

      UCB (PK) currently has 379,189,796 shares outstanding. The market capitalization of UCB (PK) is $36.64 billion. UCB (PK) has a price to earnings ratio (PE ratio) of 209.21.

      Ask ADVFN Intelligence (AI)

      UCBJY Latest News

      More News

      UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services

      UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services Judges highlight value-added partnership and finance transformation as leading examples of innovation in...

      July 01 2015
      PR Newswire (US)

      New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S.

      New Data Identify Important Factors that May Reduce Hospitalizations among People with Epilepsy in the U.S. Results of retrospective analysis show use of newer anti-epilepsy drugs, access to...

      June 16 2015
      PR Newswire (US)

      UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

      UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015 PR Newswire ATLANTA, May 16, 2015 ATLANTA, May 16, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company...

      May 16 2015
      PR Newswire (US)

      UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam

      UCB announces US and EU regulatory filings for the investigational antiepileptic drug brivaracetam - Major milestone for brivaracetam is latest step towards UCB goal of extending treatment...

      January 21 2015
      PR Newswire (US)

      UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annua...

      UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annual Meeting PR Newswire ATLANTA, Dec. 8, 2014 ATLANTA, Dec. 8, 2014...

      December 08 2014
      PR Newswire (US)

      UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of...

      UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy -- Primary efficacy and safety...

      December 08 2014
      PR Newswire (US)

      UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care

      UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care - Atlanta-based Collaboration Will Explore the Potential of Big Data to Help Inform...

      December 04 2014
      PR Newswire (US)

      UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

      UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES) - 24 UCB-sponsored presentations including new data on VIMPAT® (lacosamide) - First...

      December 03 2014
      PR Newswire (US)

      UCB shows strong scientific presence at leading rheumatology meeting

      UCB shows strong scientific presence at leading rheumatology meeting -- Data to be presented at the ACR/ARHP Annual Meeting on UCB's marketed product CIMZIA® (certolizumab pegol) and the...

      November 14 2014
      PR Newswire (US)

      Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB

      Advent International and Avista Capital Partners to Acquire Kremers Urban Pharmaceuticals from UCB PR Newswire BOSTON and NEW YORK, Nov. 7, 2014 BOSTON and NEW YORK, Nov. 7, 2014 /PRNewswire/...

      November 07 2014
      PR Newswire (US)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.20.20500205002197.5698.1194.692565697.05987179DR
      4-2.75-2.73604616456100.51100.6693.222994597.23383183DR
      129.3810.613260918888.38100.6686.711580796.62958118DR
      2614.417.274472168983.36100.6682.41634795.09988901DR
      5250.2105.55088309547.56100.6647.561892680.14640752DR
      15647.2293.430945785550.54100.6632.822092953.05958969DR
      26049.981104.60871931247.779100.6632.452030253.64915484DR

      UCBJY - Frequently Asked Questions (FAQ)

      What is the current UCB (PK) share price?
      The current share price of UCB (PK) is $ 97.76
      How many UCB (PK) shares are in issue?
      UCB (PK) has 379,189,796 shares in issue
      What is the market cap of UCB (PK)?
      The market capitalisation of UCB (PK) is USD 36.64B
      What is the 1 year trading range for UCB (PK) share price?
      UCB (PK) has traded in the range of $ 47.56 to $ 100.66 during the past year
      What is the PE ratio of UCB (PK)?
      The price to earnings ratio of UCB (PK) is 209.21
      What is the cash to sales ratio of UCB (PK)?
      The cash to sales ratio of UCB (PK) is 14.74
      What is the reporting currency for UCB (PK)?
      UCB (PK) reports financial results in EUR
      What is the latest annual turnover for UCB (PK)?
      The latest annual turnover of UCB (PK) is EUR 4.87B
      What is the latest annual profit for UCB (PK)?
      The latest annual profit of UCB (PK) is EUR 343M
      What is the registered address of UCB (PK)?
      The registered address for UCB (PK) is 60, ALLEE DE LA RECHERCHE, BRUSSELS, BRUSSELS-CAPITAL REGION, B-1070
      What is the UCB (PK) website address?
      The website address for UCB (PK) is www.ucb.com
      Which industry sector does UCB (PK) operate in?
      UCB (PK) operates in the CHEMICALS & ALLIED PRODUCTS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      SHWZMedicine Man Technologies Inc (CE)
      $ 0.0011
      (109,900.00%)
      		530
      ZHCLFZenith Capital Corporation (CE)
      $ 0.10
      (99,900.00%)
      		6k
      GNCAQGenocea Biosciences Inc (CE)
      $ 0.0005
      (49,900.00%)
      		2k
      CCTLCoin Citadel (PK)
      $ 0.0002
      (19,900.00%)
      		509.6k
      TPTWTPT Global Tech Inc (CE)
      $ 0.0002
      (19,900.00%)
      		25.08M
      BRGOBergio International Inc (PK)
      $ 0.000001
      (-99.00%)
      		502k
      POLCQPolished Inc (CE)
      $ 0.000001
      (-99.00%)
      		130
      PUGEPuget Technologies Inc (CE)
      $ 0.000001
      (-99.00%)
      		169k
      COSGCosmos Group Holdings Inc (PK)
      $ 0.000001
      (-99.00%)
      		10M
      RNWFRenewal Fuels Inc (CE)
      $ 0.000001
      (-99.00%)
      		133
      IMTLImage Protect Inc (PK)
      $ 0.0001
      (-33.33%)
      		289.87M
      ABQQAB International Group Corporation (PK)
      $ 0.0003
      (-25.00%)
      		286.78M
      PDGOParadigm Oil and Gas Inc (PK)
      $ 0.0001
      (0.00%)
      		225.08M
      BOMObowmo Inc (PK)
      $ 0.0005
      (66.67%)
      		211.25M
      RONNRonn Motor Group Inc (PK)
      $ 0.0003
      (0.00%)
      		187.29M

      Discussion

      View Full Feed
      StayHumble StayHumble 7 minutes ago
      💹 7/7/23 $HCMC entered a✅VapePatent LicensingAgreement 💹 wow

      Granting licensee a non-exclusive right & license to make|use|offer|sell, sell,& import licensed products in the USA. Licensee will pay based on net sales of all products @healthiercmc

      h
      HCMC
      shajandr shajandr 7 minutes ago
      Non-viable, non-commercializable mineral rights generally don't get financed and don't become operating mines. They remain low-cost mineral rights that get leased to unknown, low-quality entities for low lease terms - just like Elk Creek. They are used by the low-tier lessees as a story to use to ra
      NB
      TexasMarvL TexasMarvL 7 minutes ago
      Oh.  Interesting.   Mr Neumeyer already owns 5% of Snowline Gold.  His name does not appear on the New Found Gold presentation.  However,  Eric Sprott has apparently invested $260 million into New Found Gold.  I guess that is his own money.  Not sure.
      FFMGF
      The ELTP King The ELTP King 8 minutes ago
      What else is new?

      King was right
      ELTP
      zakattack zakattack 9 minutes ago
      Why keep gncp around to do nothing wtf is the point
      GNCP
      Zorax Zorax 9 minutes ago
      Ben sure loves ragging on cheeto mussolini, who doesn't, and orange shitty pants left early, I don't have any info if he was booed when he wandered around looking lost pre game, but he left early and made a big stink about the gulf of America on his plane on the way there, our tax money of course. I
      StayHumble StayHumble 10 minutes ago
      idiot, are10ks💹8ks✅ALJs m00t? SEC FAV0URS $DBMM💹
      Meaning the ruling? +1

      Source: https://www.sec.gov/alj/aljdec/2019/id1389cff.pdf
      No available sanction appropriate|Thus Proceeding Dismissed.
      -------------------------------V. ORDER
      DBMM
      blackhawks blackhawks 10 minutes ago
      Agree on the halftime show; give me Lady Gaga and Bradley Cooper reprising their A Star is Born hit with John Baptize on piano and a N.O. jazz funeral march....appropriate for KC at that point......and it would have been fine for me.
      HoldEm777 HoldEm777 11 minutes ago
      Just wanted to say thanks again for seeing through the BS, Hope all is well. $RDAR

      https://www.youtube.com/shorts/cNfYoCUFWHE
      RDAR
      DiscoverGold DiscoverGold 11 minutes ago
      $NVDA’s monthly BX is red, signaling a potential pullback before another run...
      By: Peter DiCarlo | February 9, 2025

      • $NVDA Update – Hope I’m Wrong… But

      $NVDA’s monthly BX is red, signaling a potential pullback before another run.

      Not shortin
      NVDA
      georgie18 georgie18 11 minutes ago
      Tariffs are a bargaining tool…a conduit to achieve the real goal…it’s easy to look for the obvious …never look for the obvious but what it leads too…🥳
      Vexari Vexari 11 minutes ago
      Game plan

      Allowing those

      To show their true colors

      Tickets to the rodeo

      horsesandfoals.com/wp-content/uploads/2019/05/rodeo-1249437_1280-compressor.jpg

      Are free they should start with the one's most vocal against the audits
      StayHumble StayHumble 11 minutes ago
      perForbes Insiders CE0💹KevinLamb✅T0P10 Healthcare innovators💹Forbes wow! $UBQU
      https://x.com/CorporateUbqu/status/1802724359762506049

      https://investorshub.advfn.com/uimage/uploads/2025/1/2/amsjgsuckasscurrentlybitch.png
      UBQU
      newmedman newmedman 12 minutes ago
      https://www.themirror.com/sport/american-football/donald-trump-philadelphia-eagles-superbowl-945192

      https://www.the-sun.com/sport/13471064/philadelphia-eagles-white-house-super-bowl-trump-snub/
      gemstar66 gemstar66 12 minutes ago
      ???
      AABB
      DiscoverGold DiscoverGold 13 minutes ago
      $TSLA Update – It’s Almost Time!...
      By: Peter DiCarlo | February 9, 2025

      • $TSLA Update – It’s Almost Time!

      $TSLA is pulling back into weekly market bias, a level that’s held three times before—where big money typically steps in.

      Watching the
      TSLA
      StayHumble StayHumble 14 minutes ago
      💹wow 90-$100 INCOMING!✅ UCLA💹Xerox|Mercedes|Santander|AbbeyRoadInst|Chatsworth|Ernst&Young|Omnisport|PinsentMasons
      https://www.dbmmgroup.com/wp-content/uploads/2024/03/DBMM_Creds_Deck_2024_2.pdf
      https://investorshub.advfn.com/uimage/uploads/2024/12/23/betnvDBMMi
      DBMM
      getmenews getmenews 15 minutes ago
      When did it start trading on ROBINHOOD again
      XRPUSD

      Your Recent History

      USOTC
      UCBJY
      UCB (PK)
      LSE
      AEWU
      Aew Uk Reit
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads